You will be redirected to our submission process. GLP-1 receptor agonists have gained popularity due to their dual benefits in managing Type-II diabetes and promoting significant weight loss. The ...

Researchers from McGill University reviewed 26 RCTs comprising 15,491 participants investigating 12 GLP-1 RAs and co-agonists for treating obesity in adults without diabetes. Twelve GLP-1 RA ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP ... 1 or more diabetes complication and frailty. “Regardless, our study provides ...

Adverse events were frequent (80 to 97% versus 63 to 100% for GLP-1 RA versus placebo); most were gastrointestinal-related, including nausea, vomiting, diarrhea, and constipation. "Our results ...

Drucker has identified multiple new physiological and pharmacological mechanisms of GLP-1 action, while characterizing the safety of GLP-1R agonists now utilized therapeutically for type 2 diabetes ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous ...